Baseline characteristics of the study population separately for the determined trajectories (N = 12 062)
| Characteristic . | Slow eGFR decline (n = 8954) . | Intermediate eGFR decline (n = 895) . | Fast eGFR decline (n = 222) . | Increase/stable eGFR (n = 1991) . | ||||
|---|---|---|---|---|---|---|---|---|
| Summary statistic . | n . | Summary statistic . | n . | Summary statistic . | n . | Summary statistic . | n . | |
| Age, years (n = 12 062) | 66.3 ± 11.1 | 8954 | 73.2 ± 9.1 | 895 | 65.4 ± 6.9 | 222 | 67.5 ± 9.3 | 1991 |
| Sex, women (n = 12 062) | 5173 (57.8%) | 8954 | 492 (55.0%) | 895 | 94 (42.3%) | 222 | 1318 (66.2%) | 1991 |
| BMI, kg/m2 (n = 9829) | 27.1 ± 4.2 | 7356 | 27.9 ± 4.0 | 669 | 28.9 ± 4.7 | 175 | 27.4 ± 4.2 | 1629 |
| Smoking (n = 10 052) | 7500 | 705 | 185 | 1662 | ||||
| Never | 2455 (32.7%) | 211 (29.9%) | 37 (20.0%) | 590 (35.5%) | ||||
| Past | 3540 (47.2%) | 348 (49.4%) | 92 (49.7%) | 822 (49.5%) | ||||
| Current | 1505 (20.1%) | 146 (20.7%) | 56 (30.3%) | 250 (15.0%) | ||||
| Alcohol, g/day (n = 8272) | 6.3 (0.5–14.3) | 6253 | 2.9 (0.1–14.3) | 602 | 4.6 (0.1–15.0) | 148 | 4.9 (0.5–15.0) | 1269 |
| eGFR, mL/min/1.73m2 (n = 12 062) | 79.1 ± 15.5 | 8954 | 69.1 ± 23.5 | 895 | 69.2 ± 28.7 | 222 | 73.1 ± 12.2 | 1991 |
| Serum cholesterol, mmol/L (n = 9871) | 5.7 ± 1.0 | 7387 | 5.6 ± 1.1 | 675 | 5.6 ± 1.1 | 175 | 5.8 ± 1.0 | 1634 |
| Serum triglyceride, mmol/L (n = 9902) | 1.5 ± 0.8 | 7412 | 1.7 ± 0.9 | 678 | 1.8 ± 1.0 | 174 | 1.5 ± 0.8 | 1638 |
| Systolic blood pressure, mmHg (n = 9927) | 139 ± 21 | 7432 | 149 ± 23 | 683 | 147 ± 23 | 174 | 140 ± 21 | 1638 |
| Diastolic blood pressure, mmHg (n = 9927) | 79 ± 11 | 7432 | 77 ± 12 | 683 | 80 ± 12 | 174 | 79 ± 11 | 1638 |
| Hypertension (n = 9730) | 4466 (60.4%) | 7939 | 584 (84.1%) | 694 | 145 (80.6%) | 180 | 1055 (64.5%) | 1635 |
| Diabetes, n (valid %) (n = 10 337) | 836 (10.8%) | 7716 | 168 (22.9%) | 735 | 68 (36.0%) | 189 | 174 (10.3%) | 1697 |
| History of CVD (n = 10 286) | 600 (7.8%) | 7676 | 109 (14.9%) | 733 | 34 (18.1%) | 188 | 122 (7.2%) | 1689 |
| Use of antihypertensive medication (n = 9796)a | 2217 (30.3%) | 7316 | 352 (52.1%) | 675 | 101 (57.1%) | 177 | 597 (36.7%) | 1628 |
| Use of lipid-lowering medication (n = 10 920)a | 579 (7.1%) | 8146 | 155 (20.1%) | 772 | 31 (15.5%) | 200 | 130 (7.2%) | 1802 |
| Use of cardiac medication (n = 10 920)a | 1282 (15.7%) | 8146 | 128 (16.6%) | 772 | 51 (25.5%) | 200 | 319 (17.7%) | 1802 |
| Follow-up time, years (n = 12 062) | 8.9 (6.7–14.9) | 8954 | 10.9 (6.7–15.3) | 772 | 7.5 (5.0–10.5) | 222 | 15.0 (10.2–16.5) | 1991 |
| Baseline urinary ACR, mg/g (n = 3362)b | 3.5 (2.2–6.2) | 2940 | 6.7 (3.6–17.0) | 68 | 5.5 (3.3–30.2) | 51 | 3.3 (2.1–6.3) | 303 |
| Follow-up urinary ACR, mg/g (n = 5945)b | 3.6 (2.0–7.9) | 4489 | 9.0 (4.1–31.2) | 636 | 15.4 (2.7–62.9) | 167 | 4.4 (31.2–10.1) | 825 |
| Number of repeated assessments from RS/total number of assessments (n = 12 062)c | 13 228/52 998 (25.0%) | 8954 | 1108/10 112 (11.0%) | 895 | 261/2080 (12.5%) | 222 | 3309/20 732 (16.0%) | 1991 |
| Characteristic . | Slow eGFR decline (n = 8954) . | Intermediate eGFR decline (n = 895) . | Fast eGFR decline (n = 222) . | Increase/stable eGFR (n = 1991) . | ||||
|---|---|---|---|---|---|---|---|---|
| Summary statistic . | n . | Summary statistic . | n . | Summary statistic . | n . | Summary statistic . | n . | |
| Age, years (n = 12 062) | 66.3 ± 11.1 | 8954 | 73.2 ± 9.1 | 895 | 65.4 ± 6.9 | 222 | 67.5 ± 9.3 | 1991 |
| Sex, women (n = 12 062) | 5173 (57.8%) | 8954 | 492 (55.0%) | 895 | 94 (42.3%) | 222 | 1318 (66.2%) | 1991 |
| BMI, kg/m2 (n = 9829) | 27.1 ± 4.2 | 7356 | 27.9 ± 4.0 | 669 | 28.9 ± 4.7 | 175 | 27.4 ± 4.2 | 1629 |
| Smoking (n = 10 052) | 7500 | 705 | 185 | 1662 | ||||
| Never | 2455 (32.7%) | 211 (29.9%) | 37 (20.0%) | 590 (35.5%) | ||||
| Past | 3540 (47.2%) | 348 (49.4%) | 92 (49.7%) | 822 (49.5%) | ||||
| Current | 1505 (20.1%) | 146 (20.7%) | 56 (30.3%) | 250 (15.0%) | ||||
| Alcohol, g/day (n = 8272) | 6.3 (0.5–14.3) | 6253 | 2.9 (0.1–14.3) | 602 | 4.6 (0.1–15.0) | 148 | 4.9 (0.5–15.0) | 1269 |
| eGFR, mL/min/1.73m2 (n = 12 062) | 79.1 ± 15.5 | 8954 | 69.1 ± 23.5 | 895 | 69.2 ± 28.7 | 222 | 73.1 ± 12.2 | 1991 |
| Serum cholesterol, mmol/L (n = 9871) | 5.7 ± 1.0 | 7387 | 5.6 ± 1.1 | 675 | 5.6 ± 1.1 | 175 | 5.8 ± 1.0 | 1634 |
| Serum triglyceride, mmol/L (n = 9902) | 1.5 ± 0.8 | 7412 | 1.7 ± 0.9 | 678 | 1.8 ± 1.0 | 174 | 1.5 ± 0.8 | 1638 |
| Systolic blood pressure, mmHg (n = 9927) | 139 ± 21 | 7432 | 149 ± 23 | 683 | 147 ± 23 | 174 | 140 ± 21 | 1638 |
| Diastolic blood pressure, mmHg (n = 9927) | 79 ± 11 | 7432 | 77 ± 12 | 683 | 80 ± 12 | 174 | 79 ± 11 | 1638 |
| Hypertension (n = 9730) | 4466 (60.4%) | 7939 | 584 (84.1%) | 694 | 145 (80.6%) | 180 | 1055 (64.5%) | 1635 |
| Diabetes, n (valid %) (n = 10 337) | 836 (10.8%) | 7716 | 168 (22.9%) | 735 | 68 (36.0%) | 189 | 174 (10.3%) | 1697 |
| History of CVD (n = 10 286) | 600 (7.8%) | 7676 | 109 (14.9%) | 733 | 34 (18.1%) | 188 | 122 (7.2%) | 1689 |
| Use of antihypertensive medication (n = 9796)a | 2217 (30.3%) | 7316 | 352 (52.1%) | 675 | 101 (57.1%) | 177 | 597 (36.7%) | 1628 |
| Use of lipid-lowering medication (n = 10 920)a | 579 (7.1%) | 8146 | 155 (20.1%) | 772 | 31 (15.5%) | 200 | 130 (7.2%) | 1802 |
| Use of cardiac medication (n = 10 920)a | 1282 (15.7%) | 8146 | 128 (16.6%) | 772 | 51 (25.5%) | 200 | 319 (17.7%) | 1802 |
| Follow-up time, years (n = 12 062) | 8.9 (6.7–14.9) | 8954 | 10.9 (6.7–15.3) | 772 | 7.5 (5.0–10.5) | 222 | 15.0 (10.2–16.5) | 1991 |
| Baseline urinary ACR, mg/g (n = 3362)b | 3.5 (2.2–6.2) | 2940 | 6.7 (3.6–17.0) | 68 | 5.5 (3.3–30.2) | 51 | 3.3 (2.1–6.3) | 303 |
| Follow-up urinary ACR, mg/g (n = 5945)b | 3.6 (2.0–7.9) | 4489 | 9.0 (4.1–31.2) | 636 | 15.4 (2.7–62.9) | 167 | 4.4 (31.2–10.1) | 825 |
| Number of repeated assessments from RS/total number of assessments (n = 12 062)c | 13 228/52 998 (25.0%) | 8954 | 1108/10 112 (11.0%) | 895 | 261/2080 (12.5%) | 222 | 3309/20 732 (16.0%) | 1991 |
Data are presented as number (%), mean ± SD, or median (interquartile range). Values are given for non-imputed data. The n represents the number of participants without missing data.
The following World Health Organization Anatomical Therapeutic Chemical codes were used to define medication use: cardiac medication, C01; lipid-lowering medication, C10; and blood-pressure-lowering medication, consisting of antihypertensives, C02; diuretics, C03; beta blockers, C07; calcium-channel blockers, C08; and renin–angiotensin–aldosterone system modifying agents, C09.
Urinary ACR was only available at baseline in participants from the third Rotterdam Study cohort. Data were available for participants from all three cohorts at a later visit during follow-up (collected between 2009 and 2015).
Total number of repeated assessments = 85 922; total number of repeated assessments from the Rotterdam Study = 17 906; total number of repeated assessments from the Star-MDC database = 68 016.
ACR, albumin-to-creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; n, number; RS, Rotterdam Study.
Baseline characteristics of the study population separately for the determined trajectories (N = 12 062)
| Characteristic . | Slow eGFR decline (n = 8954) . | Intermediate eGFR decline (n = 895) . | Fast eGFR decline (n = 222) . | Increase/stable eGFR (n = 1991) . | ||||
|---|---|---|---|---|---|---|---|---|
| Summary statistic . | n . | Summary statistic . | n . | Summary statistic . | n . | Summary statistic . | n . | |
| Age, years (n = 12 062) | 66.3 ± 11.1 | 8954 | 73.2 ± 9.1 | 895 | 65.4 ± 6.9 | 222 | 67.5 ± 9.3 | 1991 |
| Sex, women (n = 12 062) | 5173 (57.8%) | 8954 | 492 (55.0%) | 895 | 94 (42.3%) | 222 | 1318 (66.2%) | 1991 |
| BMI, kg/m2 (n = 9829) | 27.1 ± 4.2 | 7356 | 27.9 ± 4.0 | 669 | 28.9 ± 4.7 | 175 | 27.4 ± 4.2 | 1629 |
| Smoking (n = 10 052) | 7500 | 705 | 185 | 1662 | ||||
| Never | 2455 (32.7%) | 211 (29.9%) | 37 (20.0%) | 590 (35.5%) | ||||
| Past | 3540 (47.2%) | 348 (49.4%) | 92 (49.7%) | 822 (49.5%) | ||||
| Current | 1505 (20.1%) | 146 (20.7%) | 56 (30.3%) | 250 (15.0%) | ||||
| Alcohol, g/day (n = 8272) | 6.3 (0.5–14.3) | 6253 | 2.9 (0.1–14.3) | 602 | 4.6 (0.1–15.0) | 148 | 4.9 (0.5–15.0) | 1269 |
| eGFR, mL/min/1.73m2 (n = 12 062) | 79.1 ± 15.5 | 8954 | 69.1 ± 23.5 | 895 | 69.2 ± 28.7 | 222 | 73.1 ± 12.2 | 1991 |
| Serum cholesterol, mmol/L (n = 9871) | 5.7 ± 1.0 | 7387 | 5.6 ± 1.1 | 675 | 5.6 ± 1.1 | 175 | 5.8 ± 1.0 | 1634 |
| Serum triglyceride, mmol/L (n = 9902) | 1.5 ± 0.8 | 7412 | 1.7 ± 0.9 | 678 | 1.8 ± 1.0 | 174 | 1.5 ± 0.8 | 1638 |
| Systolic blood pressure, mmHg (n = 9927) | 139 ± 21 | 7432 | 149 ± 23 | 683 | 147 ± 23 | 174 | 140 ± 21 | 1638 |
| Diastolic blood pressure, mmHg (n = 9927) | 79 ± 11 | 7432 | 77 ± 12 | 683 | 80 ± 12 | 174 | 79 ± 11 | 1638 |
| Hypertension (n = 9730) | 4466 (60.4%) | 7939 | 584 (84.1%) | 694 | 145 (80.6%) | 180 | 1055 (64.5%) | 1635 |
| Diabetes, n (valid %) (n = 10 337) | 836 (10.8%) | 7716 | 168 (22.9%) | 735 | 68 (36.0%) | 189 | 174 (10.3%) | 1697 |
| History of CVD (n = 10 286) | 600 (7.8%) | 7676 | 109 (14.9%) | 733 | 34 (18.1%) | 188 | 122 (7.2%) | 1689 |
| Use of antihypertensive medication (n = 9796)a | 2217 (30.3%) | 7316 | 352 (52.1%) | 675 | 101 (57.1%) | 177 | 597 (36.7%) | 1628 |
| Use of lipid-lowering medication (n = 10 920)a | 579 (7.1%) | 8146 | 155 (20.1%) | 772 | 31 (15.5%) | 200 | 130 (7.2%) | 1802 |
| Use of cardiac medication (n = 10 920)a | 1282 (15.7%) | 8146 | 128 (16.6%) | 772 | 51 (25.5%) | 200 | 319 (17.7%) | 1802 |
| Follow-up time, years (n = 12 062) | 8.9 (6.7–14.9) | 8954 | 10.9 (6.7–15.3) | 772 | 7.5 (5.0–10.5) | 222 | 15.0 (10.2–16.5) | 1991 |
| Baseline urinary ACR, mg/g (n = 3362)b | 3.5 (2.2–6.2) | 2940 | 6.7 (3.6–17.0) | 68 | 5.5 (3.3–30.2) | 51 | 3.3 (2.1–6.3) | 303 |
| Follow-up urinary ACR, mg/g (n = 5945)b | 3.6 (2.0–7.9) | 4489 | 9.0 (4.1–31.2) | 636 | 15.4 (2.7–62.9) | 167 | 4.4 (31.2–10.1) | 825 |
| Number of repeated assessments from RS/total number of assessments (n = 12 062)c | 13 228/52 998 (25.0%) | 8954 | 1108/10 112 (11.0%) | 895 | 261/2080 (12.5%) | 222 | 3309/20 732 (16.0%) | 1991 |
| Characteristic . | Slow eGFR decline (n = 8954) . | Intermediate eGFR decline (n = 895) . | Fast eGFR decline (n = 222) . | Increase/stable eGFR (n = 1991) . | ||||
|---|---|---|---|---|---|---|---|---|
| Summary statistic . | n . | Summary statistic . | n . | Summary statistic . | n . | Summary statistic . | n . | |
| Age, years (n = 12 062) | 66.3 ± 11.1 | 8954 | 73.2 ± 9.1 | 895 | 65.4 ± 6.9 | 222 | 67.5 ± 9.3 | 1991 |
| Sex, women (n = 12 062) | 5173 (57.8%) | 8954 | 492 (55.0%) | 895 | 94 (42.3%) | 222 | 1318 (66.2%) | 1991 |
| BMI, kg/m2 (n = 9829) | 27.1 ± 4.2 | 7356 | 27.9 ± 4.0 | 669 | 28.9 ± 4.7 | 175 | 27.4 ± 4.2 | 1629 |
| Smoking (n = 10 052) | 7500 | 705 | 185 | 1662 | ||||
| Never | 2455 (32.7%) | 211 (29.9%) | 37 (20.0%) | 590 (35.5%) | ||||
| Past | 3540 (47.2%) | 348 (49.4%) | 92 (49.7%) | 822 (49.5%) | ||||
| Current | 1505 (20.1%) | 146 (20.7%) | 56 (30.3%) | 250 (15.0%) | ||||
| Alcohol, g/day (n = 8272) | 6.3 (0.5–14.3) | 6253 | 2.9 (0.1–14.3) | 602 | 4.6 (0.1–15.0) | 148 | 4.9 (0.5–15.0) | 1269 |
| eGFR, mL/min/1.73m2 (n = 12 062) | 79.1 ± 15.5 | 8954 | 69.1 ± 23.5 | 895 | 69.2 ± 28.7 | 222 | 73.1 ± 12.2 | 1991 |
| Serum cholesterol, mmol/L (n = 9871) | 5.7 ± 1.0 | 7387 | 5.6 ± 1.1 | 675 | 5.6 ± 1.1 | 175 | 5.8 ± 1.0 | 1634 |
| Serum triglyceride, mmol/L (n = 9902) | 1.5 ± 0.8 | 7412 | 1.7 ± 0.9 | 678 | 1.8 ± 1.0 | 174 | 1.5 ± 0.8 | 1638 |
| Systolic blood pressure, mmHg (n = 9927) | 139 ± 21 | 7432 | 149 ± 23 | 683 | 147 ± 23 | 174 | 140 ± 21 | 1638 |
| Diastolic blood pressure, mmHg (n = 9927) | 79 ± 11 | 7432 | 77 ± 12 | 683 | 80 ± 12 | 174 | 79 ± 11 | 1638 |
| Hypertension (n = 9730) | 4466 (60.4%) | 7939 | 584 (84.1%) | 694 | 145 (80.6%) | 180 | 1055 (64.5%) | 1635 |
| Diabetes, n (valid %) (n = 10 337) | 836 (10.8%) | 7716 | 168 (22.9%) | 735 | 68 (36.0%) | 189 | 174 (10.3%) | 1697 |
| History of CVD (n = 10 286) | 600 (7.8%) | 7676 | 109 (14.9%) | 733 | 34 (18.1%) | 188 | 122 (7.2%) | 1689 |
| Use of antihypertensive medication (n = 9796)a | 2217 (30.3%) | 7316 | 352 (52.1%) | 675 | 101 (57.1%) | 177 | 597 (36.7%) | 1628 |
| Use of lipid-lowering medication (n = 10 920)a | 579 (7.1%) | 8146 | 155 (20.1%) | 772 | 31 (15.5%) | 200 | 130 (7.2%) | 1802 |
| Use of cardiac medication (n = 10 920)a | 1282 (15.7%) | 8146 | 128 (16.6%) | 772 | 51 (25.5%) | 200 | 319 (17.7%) | 1802 |
| Follow-up time, years (n = 12 062) | 8.9 (6.7–14.9) | 8954 | 10.9 (6.7–15.3) | 772 | 7.5 (5.0–10.5) | 222 | 15.0 (10.2–16.5) | 1991 |
| Baseline urinary ACR, mg/g (n = 3362)b | 3.5 (2.2–6.2) | 2940 | 6.7 (3.6–17.0) | 68 | 5.5 (3.3–30.2) | 51 | 3.3 (2.1–6.3) | 303 |
| Follow-up urinary ACR, mg/g (n = 5945)b | 3.6 (2.0–7.9) | 4489 | 9.0 (4.1–31.2) | 636 | 15.4 (2.7–62.9) | 167 | 4.4 (31.2–10.1) | 825 |
| Number of repeated assessments from RS/total number of assessments (n = 12 062)c | 13 228/52 998 (25.0%) | 8954 | 1108/10 112 (11.0%) | 895 | 261/2080 (12.5%) | 222 | 3309/20 732 (16.0%) | 1991 |
Data are presented as number (%), mean ± SD, or median (interquartile range). Values are given for non-imputed data. The n represents the number of participants without missing data.
The following World Health Organization Anatomical Therapeutic Chemical codes were used to define medication use: cardiac medication, C01; lipid-lowering medication, C10; and blood-pressure-lowering medication, consisting of antihypertensives, C02; diuretics, C03; beta blockers, C07; calcium-channel blockers, C08; and renin–angiotensin–aldosterone system modifying agents, C09.
Urinary ACR was only available at baseline in participants from the third Rotterdam Study cohort. Data were available for participants from all three cohorts at a later visit during follow-up (collected between 2009 and 2015).
Total number of repeated assessments = 85 922; total number of repeated assessments from the Rotterdam Study = 17 906; total number of repeated assessments from the Star-MDC database = 68 016.
ACR, albumin-to-creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; n, number; RS, Rotterdam Study.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
